Form 4: Aligos Therapeutics Director Carole Nuechterlein Granted Stock Options

Aligos Therapeutics, Inc. Director Carole Nuechterlein was granted 5,860 stock options with an exercise price of $7.63, vesting on the earlier of the first anniversary of the grant date or prior to the 2026 annual meeting.

Summary

• Carole Nuechterlein, a Director of Aligos Therapeutics, Inc. (ALGS), was granted 5,860 stock options.
• The options have an exercise price of $7.63 per share.
• The grant date for these options was June 25, 2025.
• The options will vest 100% on the earlier of June 25, 2026 (first anniversary of the grant date) or immediately prior to the Issuer's 2026 annual stockholders meeting.
• Vesting is contingent upon continuous service to Aligos Therapeutics through the vesting date.
• The options have an expiration date of June 25, 2035.
• Following this transaction, Ms. Nuechterlein directly beneficially owns 5,860 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholder value creation. It's a standard compensation practice, indicating continued commitment.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The value of the stock options is dependent on the future stock price of Aligos Therapeutics, Inc. If the stock price does not exceed the exercise price of $7.63, the options may expire worthless.
• Vesting is subject to continuous service, meaning the director must remain with the company until the vesting date to realize the benefit.

Future Outlook

The document indicates a future vesting event for the granted stock options, contingent on continuous service, which aligns the director's future incentives with company performance.

Industry Context

This Form 4 filing represents a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, where stock options are a common tool to incentivize and retain key personnel by aligning their financial interests with long-term company success.

Related Party Transactions

• The grant of stock options to Carole Nuechterlein, a Director of Aligos Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if the options are exercised.

Next Steps

• The stock options are scheduled to vest on the earlier of June 25, 2026, or immediately prior to the 2026 annual meeting of stockholders, subject to continuous service.
• The options will expire on June 25, 2035.

Key Dates

Keywords

Aligos Therapeutics, ALGS, Stock Option, Form 4, SEC Filing, Director Compensation, Equity Grant, Beneficial Ownership, Carole Nuechterlein